Streetbeat News

NRXP

NRx Pharmaceuticals, Inc.

https://www.nrxpharma.com

Industry

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Open

1.24

Mkt cap

15M

Volume

80K

High

1.27

P/E Ratio

-0.60

52-wk high

7.33

Low

1.21

Div yield

N/A

52-wk low

1.10

NRx Pharmaceuticals has received FDA clearance for its Investigational New Drug (IND) application for NRX-101, a treatment for complicated urinary tract infections (UTIs). This regulatory milestone allows NRx Pharmaceuticals to proceed with clinical trials for NRX-101, potentially advancing the treatment options for patients with complicated UTIs.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 11:50 am

In Monday's after-market session, several healthcare stocks experienced significant movements. Connect Biopharma Hldgs (CNTB) saw a 51.1% increase, while IN8bio (INAB) rose by 14.84%, and Inotiv (NOTV) by 13.85% following their Q4 earnings release. OneMedNet (ONMD), AquaBounty Techs (AQB), and Cue Health (HLTH) also saw gains. Conversely, Assure Hldgs (IONM), Pasithea Therapeutics (KTTA), Lucy Scientific Discovery (LSDI), Onconova Therapeutics (ONTX), Exicure (XCUR), and NRX Pharmaceuticals (NRXP) experienced declines.

Portfolio Pulse from Benzinga Insights

December 11, 2023 | 9:31 pm

In Wednesday's after-market session, several healthcare stocks experienced significant movements. Telesis Bio (TBIO) led the gainers with a 32.5% increase, while Impel Pharmaceuticals (IMPL) saw the largest decline among the losers, dropping 13.3%. Other notable movers included Femasys (FEMY), Axcella Health (AXLA), and Gyre Therapeutics (GYRE), which released its Q1 earnings report.

Portfolio Pulse from Benzinga Insights

November 22, 2023 | 9:31 pm

The article lists a number of companies scheduled to report their earnings on November 14, 2023. It includes their expected quarterly results, with some companies anticipated to report profits per share and others expected to report losses. The revenues for each company are also provided, giving investors insights into the financial performance of these companies for the upcoming earnings announcements.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 1:23 pm

NRX Pharmaceuticals (NASDAQ:NRXP) reported a Q3 EPS loss of $(0.07), surpassing the consensus estimate of $(0.12) by 41.67%. The reported loss shows a 50% improvement from the $(0.14) per share loss in the same quarter of the previous year.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 2:01 am

NRX Pharmaceuticals (NASDAQ:NRXP) is scheduled to release its quarterly earnings report on November 14, 2023. Analysts predict an EPS of $-0.12. Investors will be looking for an earnings beat and positive guidance for future growth. Historically, NRXP's stock price has reacted to past earnings performances, with a mix of positive and negative changes post-announcement. The stock is currently trading at $0.3299, down 64.57% over the last 52 weeks.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 4:02 pm

NRx Pharmaceuticals and Nephron Pharmaceuticals have signed an agreement to manufacture a version of Ketamine for treating suicidal depression. The partners aim to submit a New Drug Application by March 1, 2024, and target a finished drug with two-year shelf stability for November 2024, pending FDA approval.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:55 am

NRx Pharmaceuticals has signed a contract to develop a version of Ketamine suitable for intravenous administration under current FDA manufacturing regulations. Existing supplies of Ketamine are not labeled for treatment of depression and suicidality and often do not meet modern manufacturing requirements for single-dose injectable medications.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 11:23 am

NRx Pharmaceuticals has announced a strategic acceleration of its plans to develop a commercial form of NRX-100 (Intravenous Ketamine) to treat acute depression and suicidality.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 10:50 am

Delta Apparel shares rose by 8.1% in pre-market trading after the company received an unsolicited offer to purchase its Salt Life business. Other notable pre-market movers include VIQ Solutions, Molekule Group, AgileThought, ALX Oncology Holdings, SIGNA Sports United, Loop Media, Renalytix, MSP Recovery, and SeaStar Medical Holding. On the losing side, AERWINS Technologies, SmileDirectClub, Nisun International Enterprise Development Group, Actelis Networks, NRx Pharmaceuticals, Eastside Distilling, OpGen, Better Choice Company, IceCure Medical, and Femasys saw declines.

Portfolio Pulse from Lisa Levin

October 03, 2023 | 12:02 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.